CAS: 56-03-1; Biguanide
该化合物是有机化合物,其独特结构具有特征,包含两个由碳链连接的瓜尼丁组;它是在水中可以溶解的白色晶状固体,具有基本特性;Biguanide主要在医疗领域使用,特别是作为治疗2型糖尿病的抗血膜血清剂,它的作用是减少肝糖生产,提高胰岛素的敏感性;此外,它被各种配方用作抗微生物剂,特别是非非感染性抗菌剂和抗菌剂;该化合物还因其毒性相对较低而显著,但与其他类似制剂相比,它可造成胃肠侧效应,在罕见的情况下,可造成肺酸性中毒;就化学特性而言,大氮素可形成盐类和复合体,其再活性受其结构中功能组的存在影响;
- 英文名称Biguanide
- 中文名称双胍
- IUPAC名称Biguanide
- 其它别名Biguanide; Amidinoguanidine; 1-(Diaminomethylidene)Guanidine; Diguanide; Guanylguanidine; 1-(Diaminomethylene)Guanidine; 2,4-Diimino-1,3,5-Triazapentane; 2-Amidinoguanidine
- CAS编号56-03-1
- MFCD编号:MFCD00045592
- EINECS号:200-251-8
- FDA UNII编号:FB4Q52I9K2
- 分子式:C2H7N5分子量:101.11
- 产品CID: 2304658
- 产品分类有机原料→分子砌块→脂肪链类化合物
- 相似结构搜索
- 产品信息参考
; - InChIKey: XNCOSPRUTUOJCJ-UHFFFAOYSA-N
- InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)
- 计算化学: 氢键受体数2.0氢键供体数5.0可旋转键数*
相似化合物
4761-93-7 1674-62-0 21770-81-0物理性质
MSDS等安全信息
上下游产品
guanidine hydr°Chloride biguanide hydrogen chloride biguanide sulfate CYANAMID6-(5-nitro-furan-2-yl)-[1,3,5]triazine-2,4-diamine 2,4-diamino-6-(2-furyl)-1,3,5-triazine 2-methyl-4,6-diamino-1,3,5-triazine 2,4-diamino-1,3,5-triazine合成工艺路线路线简述
📜2-甲脒基胍硫酸盐置于乙醇,Sodium体系中,化学反应生成 双胍
参考文献:Slotta; Tschesche,Chemische Berichte,1929,Vol. 62,P. 1394
标题:Slotta; Tschesche,Chemische Berichte,1929,Vol. 62,P. 1394
专利信息
专利号:US-8815351-B2
优先权日:2005-09-15
标 题:Method for attachment of silicon-containing compounds to a surface and for synthesis of hypervalent silicon-compounds
发明人：OWENS JEFFREY R
权利人:OWENS JEFFREY R; US AIR FORCE
摘要:A method for attaching silicon-containing compounds to a surface and for synthesis of hypervalent silicon-compounds is described. Attaching silicon-containing compounds to a surface comprises providing a silicon-containing compound having two or more leaving groups, and a first functional compound comprising at least one nucleophilic group, contacting the silicon-containing compound and the functional compound with a surface of a substrate having nucleophilic sites and exposing the silicon-containing compound, the functional compound and the surface of the substrate to microwave radiation.
专利号:US-4579946-A
优先权日:1985-01-10
标 题:Process for synthesis of 2-vinyl-4,6-diamino-S-triazine
发明人：SAWA NATSUO; MASUDA TAKESHI
权利人:SHIKOKU CHEM
摘要:Disclosed is a process for the synthesis of 2-vinyl-4,6-diamino-S-triazine having the following structural formula: ##STR1## which comprises heating an imidazolyl-S-triazine compound represented by the following general formula: ##STR2## wherein R 1 stands for a hydrogen atom, a methyl group or an ethyl group, and R 2 stands for a hydrogen atom or a methyl group, or an isocyanuric acid-addition product thereof under reduced pressure in the presence of a polymerization inhibitor. n According to this process, 2-vinyl-4,6-diamino-S-triazine can be manufactured at a low cost on an industrial scale.
专利号:US-7947701-B2
优先权日:2003-11-14
标题:Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
发明人：CAZELLES JEROME; COSLEDAN FREDERIC; MEUNIER BERNARD; PELLET ALAIN
权利人:SANOFI AVENTIS
摘要:The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.
专利号:US-2013243770-A1
优先权日:2005-10-14
标 题:Treating diabetes using inhibitors of il-1
发明人：LAU JESPER
权利人:NOVO NORDISK AS
摘要:The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.
专利号:US-2006105940-A1
优先权日:2004-11-03
标题:Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods
发明人：GREIG NIGEL H; BRUINSMA GOSSE B; YU QIAN-SHENG
权利人:AXONYX INC
摘要:Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (−)-(3aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N—4′-isopropylphenylcarbamate (“MHI tartrateâ€?), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects may be suffering from or predicted to suffer from abnormal acetylcholinesterase and/or butyrylcholinesterase activity levels or from an inability to metabolize or catabolize blood sugar normally. The method comprises administering to the subject an effective amount of MHI tartrate dispensable in discrete pharmaceutically useful dosages. MHI tartrate effectively inhibits both acetylcholinesterase and butyrylcholinesterases and additionally is highly selective for butyrylcholinesterase over acetylcholinesterase.
专利号:US-7956214-B2
优先权日:2001-11-02
标题 :Process for the preparation of aniline-derived thyroid receptor ligands
发明人：CHIDAMBARAM RAMAKRISHNAN; KANT JOYDEEP; WEAVER RAYMOND E; YU JURONG; GHOSH ARUN
权利人:KAROBIO AB; BRISTOL MYERS SQUIBB CO
摘要:Provided are processes for the synthesis of aniline derivatives, specifically certain aniline derivatives which have activity as thyroid receptor ligands.
